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Summary
 
Although apoptosis is considered one of the major mechanisms of CD4
 
1
 
 T cell depletion in
HIV-infected patients, the virus-infected cells somehow appear to be protected from apoptosis,
which generally occurs in bystander cells. Vpr is an auxiliary HIV-1 protein, which, unlike the
other regulatory gene products, is present at high copy number in virus particles. We estab-
lished stable transfectants of CD4
 
1
 
 T Jurkat cells constitutively expressing low levels of vpr.
These clones exhibited cell cycle characteristics similar to those of control-transfected cells.
Treatment of control clones with apoptotic stimuli (i.e., cycloheximide/tumor necrosis factor
 
a
 
 (TNF-
 
a
 
), anti-Fas antibody, or serum starvation) resulted in a massive cell death by apopto-
sis. In contrast, all the vpr-expressing clones showed an impressive protection from apoptosis
independently of the inducer. Notably, vpr antisense phosphorothioate oligodeoxynucleotides
render vpr-expressing cells as susceptible to apoptosis induced by cycloheximide and TNF-
 
a
 
 as
the control clones. Moreover, the constitutive expression of HIV-1 vpr resulted in the upregu-
lation of bcl-2, an oncogene endowed with antiapoptotic activities, and in the downmodula-
tion of bax, a proapoptotic factor of the bcl-2 family. Altogether, these results suggest that low
levels of the endogenous vpr protein can interfere with the physiological turnover of T lym-
phocytes at early stages of virus infection, thus facilitating HIV persistence and, subsequently,
viral spread. This might explain why apoptosis mostly occurs in bystander uninfected cells in
AIDS patients.
 
T
 
he human immunodeficiency virus type I (HIV-1)
displays a high level of genetic complexity, which ac-
counts for its tightly regulated replication. In addition to
the structural and replicative proteins (gag, pol, and env),
HIV-1 genome specifies at least six auxiliary proteins (vif,
vpr, tat, rev, vpu, and nef) that are capable of regulating vi-
ral replication and infectivity (1, 2). The vpr accessory gene
encodes a small basic protein (15 kD) that, unlike the other
regulatory gene products, is present at high copy number in
viral particles (3–5). Incorporation of vpr into HIV-1 viri-
ons is mediated by a specific interaction with the COOH-
terminal region of the gag precursor (6–8). Because of its
virion association, it has been suggested that vpr has an early
role in HIV-1 infection, thus facilitating the transport of the
virus core into the nucleus of nondividing cells. Subse-
quently, it has been reported that, together with the viral
matrix (MA) protein, vpr plays a fundamental role in the
proviral DNA integration process by connecting the pre-
integration complex with the cell nuclear import pathway
(9, 10).
The importance of vpr for viral persistence, replication,
and pathogenesis is suggested by a number of in vivo and in
vitro studies. In particular, it has been demonstrated that, in
macaques infected with wild-type or vpr-mutant viruses, vpr
is associated with an increased viral load and rate of pro-
gression to AIDS (11). Moreover, it has also been shown that
the vpr-positive strains grow faster and produce moderately
higher levels of virus than their vpr-negative counterparts.
This enhanced virus production is more pronounced in
primary macrophages, suggesting that vpr function may be
important in specific target cells (12–14). Interestingly, this
protein does not appear to confer a significant viral growth
advantage in primary T cells (15, 16). A few reports have
also described effects of vpr on cell cycle and differentia-
tion. In fact, HIV-1 vpr expression was first noted to pro-
mote differentiation and growth inhibition of a human rhab-
domyosarcoma cell line (17). Subsequent studies revealed
that vpr produces an accumulation of cells in the G
 
2
 
/M
phase of the cell cycle, thereby preventing the establish-
ment of chronic HIV-1 infection in T lymphocytes (18–
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22). In some of these studies, vpr was shown to interact
with upstream regulators of the cyclin-associated p34cdc2
kinase, which regulates the G
 
2
 
/M transition (20, 21).
Apoptosis is a regulated mechanism of cell suicide that is
essential for normal development and homeostasis in multi-
cellular organisms and provides a defense against virus inva-
sion and oncogenesis (23). Recent evidence suggests that
most eukariotic cells respond to viral disruption of cellular
homeostasis by undergoing apoptosis (24). To counteract
this, many viruses have evolved mechanisms to block host
cell death. In several cases, viral genomes have been found
to possess genes whose products are capable of modulating,
either positively or negatively, apoptosis of their host cells
(25). Among the known examples of viral gene products
blocking apoptosis are the adenovirus E1B protein (26),
vaccinia CrmA protein (27), simian virus 40 T antigen (28),
human papilloma 16 E6 protein (29), insect baculovirus
p35 and iap proteins (30, 31), Epstein-Barr virus BHRF1
protein (32), human cytomegalovirus IE1 and IE2 gene pro-
ducts (33), herpes simplex virus 1 ICP4 (34) protein, and
the very recently described bcl-2 homologue of human her-
pes virus 8 (35). As regards to HIV, some apparently con-
trasting data are available on the possible role of the HIV-1
Tat protein in the control of apoptosis. In particular, while
Zauli and coworkers (36, 37) showed that Tat-expressing cells
were resistant to different apoptotic stimuli, including acute
HIV infection, other groups (38–41) have found that Tat
induces apoptosis in T cells. Very recently, McCloskey et al.
(42) demonstrated that Tat exhibited a dual role in the reg-
ulation of apoptosis in uninfected T cells. Although addi-
tion of exogenous Tat protein induced apoptosis in these
cells, T cell clones stably expressing the Tat protein were
protected from activation-induced apoptosis (42). Contrast-
ing results have also been recently obtained on the effect of
the HIV-1 vpr protein in the regulation of apoptosis (43,
44). In particular, Stewart et al. (43) have reported that the
ability of vpr to arrest cells in the G
 
2
 
 phase finally resulted
in cell death by apoptosis. Furthermore, a recent study by
Ayyavoo et al. (44) showed that vpr was capable of regulat-
ing, both positively or negatively, the T cell receptor trig-
gered apoptosis depending on the state of immune activa-
tion.
In this study, we report that the constitutive expression
of the HIV-1 vpr protein results in a marked inhibition of
apoptosis induced by different stimuli, such as a combina-
tion of cycloheximide (CHX)
 
1
 
 and TNF-
 
a
 
, anti-Fas antibody,
and serum starvation. To the best of our knowledge, this is
the first report in which a stable expression of low levels of
the vpr protein has been achieved. The antiapoptotic effect
of vpr is mediated, at least in part, by the regulation of the
expression of some bcl-2 family members. These data sug-
gest that the HIV-1 vpr protein is an early regulator of apo-
ptosis in HIV-infected T cells and represents an additional
survival strategy for HIV persistence and spreading.
 
Materials and Methods
 
Construction of vpr Expression Plasmids
 
The vpr open reading frame of the HIV-1 genomic clone
pBT-1, BRU strain (American Type Culture Collection, Rock-
ville, MD) was amplified by PCR with oligonucleotides 5
 
9
 
CCC-
AAGCTTGCCGCCACCATGGAACAAGCCCC and 5
 
9
 
GCT-
CTAGACTAGGATCTACTGGCTCC. Products were digested
with XbaI and cloned into the XbaI restriction site of the pRc/
CMV plasmid (Invitrogen, Carlsbad, CA), whose promoter con-
sists of a fragment of DNA from the immediate early gene of hu-
man CMV. Sequences from the bovine growth hormone gene
are 3
 
9
 
 to the vpr gene to provide both polyadenylation and tran-
scription termination site. The sequence of the vpr gene in the
expression construct was determined before transfection and
proved to be identical to the sequence of the molecular clone
used as template for vpr amplification (data not shown).
 
Cell Culture and Production of vpr Transfectants
 
The Jurkat human T cell line (clone E6-1; obtained from Na-
tional Institutes of Health AIDS Research and Reference Re-
agent Program, Bethesda, MD) was maintained in RPMI 1640
with 10% FCS and penicillin/streptomycin sulfate in 5% CO
 
2
 
 at-
mosphere. Vpr-expressing cells were isolated after electroporation
(500 
 
m
 
F, 250 V) of 5 
 
3
 
 10
 
6
 
 cells with 10 
 
m
 
g of either pRc/vpr or
pRc/neo plasmid DNA. The transfected cells were grown in RPMI
containing 10% of FCS for 48 h before the addition of G-418 (1
mg/ml). After 4 d of growth in selection medium, the neomycin-
resistant cells were seeded in RPMI containing 1% methylcellulose
and 1 mg/ml G-418 in order to isolate single vpr-positive cell clones.
The clones were maintained in RPMI medium containing 500
 
m
 
g/ml of G-418 and analyzed for vpr expression.
 
Expression of vpr in Transfectants
 
The expression of vpr messenger RNA (mRNA) in neomy-
cin-resistant clones was analyzed by RNA-PCR. For the reverse
transcription, 1 
 
m
 
g of total RNA, extracted from cells harvested
during the logarithmic growth by the method of Chirwgin (45),
was mixed with 1 
 
m
 
g of oligo dT (12–18 oligomer; Pharmacia
Biotech, Piscataway, NJ) as previously described (46). The cDNA
obtained was amplified by using 0.1 
 
m
 
g of primers specific for the
vpr or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in
a reaction mixture containing 200 
 
m
 
M dNTP and 0.5 U of Ther-
mus acquaticus (TAQ) DNA polymerase in PCR buffer (44).
PCR amplification was performed in a thermal controller (MJ
Research, Inc., Watertown, MA) for 30 cycles of 1 min at 94
 
8
 
C,
2 min at 55
 
8
 
C, and 3 min at 72
 
8
 
C. A negative control lacking
template RNA or reverse transcriptase was included in each experi-
ment (data not shown). The reaction products were visualized by
electrophoresis on 2.5% agarose gels followed by ethidium bro-
mide staining. 0.5 
 
m
 
g of HaeIII digested 
 
f
 
X174 DNA (BioLabs, Inc.,
Beverly, MA) was used as molecular weight marker. The sequences
of the GAPDH primers have been previously described (46).
For the detection of vpr protein, the neomycin-resistant cells
were lysed in a buffer containing 1% Brij 96 as previously de-
scribed (10). The cell lysates were precleared for 1 h at 4
 
8
 
C with
protein G–Sepharose (Pharmacia Biotech) and then incubated
overnight at 4
 
8
 
C with protein G–Sepharose precoated with a guinea
pig anti-vpr antibody (10). After extensive washes with the lysis
buffer, immune complexes were eluted, subjected to 18% SDS-
PAGE, and transferred to filters (ClearBlot, ATTO). The filters
were then processed for Western blotting with a guinea pig anti-
vpr antibody (10).
 
1
 
 
 
Abbreviations used in this paper:
 
 CHX, cycloheximide; GAPDH, glyceral-
dehyde-3-phosphate dehydrogenase; mRNA, messenger RNA; PI, pro-
pidium iodide. 
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Inhibition of vpr Expression by Antisense Phosphorothioate 
Oligodeoxynucleotides Targeted to vpr
 
Vpr-expressing clones were treated with phosphorothioate oli-
godeoxynucleotides targeted at the open reading frame of vpr as pre-
viously described (13). In brief, the cells were seeded at the con-
centration of 5 
 
3
 
 10
 
5
 
/ml in the presence or in the absence of 20 
 
m
 
M
of either antisense (oligonucleotide 3) or control sense (oligonu-
cleotide 4) phosphorothioate oligonucleotides (13). After 18 h at
37
 
8
 
C, both oligonucleotides were added again and 1 h later cells
were stimulated to undergo apoptosis. The extent of apoptosis was
then evaluated after 4 h by propidium iodide staining.
 
Analytical Cytology
 
Cell Cycle Analysis.
 
DNA analysis was performed by using
propidium iodide (PI; 40 
 
m
 
g/ml) as previously described (47). At
least 10,000 events have been acquired (Lysys II Software; Becton
Dickinson, Mountain View, CA). The percentage of cells in the
different phases of the cell cycle were obtained by CellFIT soft-
ware analysis. The median values were estimated by three differ-
ent methods: RFIT, SFIT, and SORB.
 
Apoptosis Assays.
 
To evaluate apoptosis, both immunofluo-
rescence and flow cytometry techniques were used. The chroma-
tin dye Hoechst 33258 (Molecular Probes Inc., Eugene, OR) was
used to visualize chromatin condensation and clumping as de-
scribed elsewhere (47). Cells were fixed with paraformaldehyde
3% in PBS. After washing, all the samples were mounted with
glycerol/PBS (1:1) and observed with a Nikon Microphot fluo-
rescence microscope. Quantitative evaluation of apoptotic cells
was performed by counting at least 12 microscopic fields in qua-
druplicate for a total amount of at least 400 cells at high magnifi-
cation (
 
3
 
500). For DNA content evaluation by flow cytometry,
the cells were fixed and permeabilized as previously described (48).
The samples were then analyzed on a FACScan
 
Ò
 
 flow cytometer
(Becton Dickinson) equipped with a 488-nm argon laser. Data
were recovered by a Hewlett Packard computer using the Lysys
II Software.
 
Quantitative Evaluation of Bcl-2 and Bax Proteins
 
Control and vpr-transfected Jurkat cells were pelleted, fixed in
70% ice-cold methanol, and washed twice with cold PBS. For
Bax detection, cells were stained for 30 min at 37
 
8
 
C with an anti-
bax polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA). After washing, cells were incubated for 30 min at
37
 
8
 
C with FITC-labeled anti–rabbit polyclonal antibody (Sigma
Chemical Co., St. Louis, MO). For the detection of bcl-2, cells
were stained with an FITC-labeled anti–bcl-2 monoclonal anti-
body (Dako Corp., Carpinteria, CA) at a final concentration of 0.1
mg/ml for 30 min at 4
 
8
 
C. After washing, all samples were imme-
diately analyzed on a FACScan
 
Ò
 
 flow cytometer as described above.
For Western blot analysis of bcl-2 and bax, whole cell extracts
(60 
 
m
 
g), prepared as previously described (36), were resolved by
10% SDS-PAGE, electrophoretically transferred to a nitrocellu-
lose membrane (Schleicher & Schuell, Keene, NH), and incu-
bated with either anti–bcl-2 mouse monoclonal antibody (Dako
Corp.; 1:100 dilution) or anti-bax rabbit polyclonal antibody (Santa
Cruz Biotechnology; 1:100 dilution) overnight at room tempera-
ture. After four washes with TBS-T, membranes were reacted
with peroxidase-conjugated anti–mouse (1:4,000 dilution) or anti–
rabbit (1:1,000) immunoglobulin sera (Amersham Corp., Arlington
Heights, IL) and visualized with the enhanced chemiluminescence
detection system (Amersham Corp.). Membranes were further
probed with antibody to 
 
b
 
-tubulin (Sigma Chemical Co.; dilu-
tion 1:200) to ensure that an equal amount of proteins were loaded
and transferred (data not shown).
 
Statistical Analysis
 
Statistical significance was evaluated by the Student’s 
 
t
 
 test for
correlated samples.
 
Reagents
 
CHX and human recombinant TNF-
 
a
 
 were purchased from
Sigma Chemical Co. Monoclonal IgM antibody to human Fas anti-
gen was obtained from Upstate Biotechnology Inc. (Lake Placid,
NY). The anti-vpr antibodies were produced by immunizing
guinea pigs with either recombinant HIV-1 vpr expressed by
pGEMEX vector or a synthetic NH
 
2
 
-terminal 14 oligopeptide of
vpr (10).
 
Results
 
Establishment and Characterization of Jurkat Cell Clones Sta-
bly Expressing the HIV-1 vpr Protein.
 
To obtain transfec-
tants expressing the HIV-1 vpr gene, the open reading
frame of the HIV-1 vpr, cloned into a pRc/CMV expres-
sion vector, was introduced into Jurkat cells by electropor-
ation. Selection with G-418 led to the isolation of six neo-
mycin-resistant clones. In parallel, the expression vector not
containing the vpr insert was also introduced into Jurkat
cells (mock transfection). Seven control neomycin-resistant
clones were isolated. Clones obtained after transfection of
pRc/CMV–vpr or pRc/CMV empty vector were screened
for vpr mRNA expression by PCR analysis. Fig. 1 
 
A
 
 shows
the results of the PCR analysis of four representative vpr-
transfected clones in which the expression of vpr transcripts
was compared with that of mock-transfected clones and
acutely HIV-infected T cells. In all vpr-transfected clones,
full-length vpr mRNA transcripts of the expected size (319
bp) were detected after amplification with vpr-specific pri-
mers. The same transcripts were detected in acutely HIV-
infected cells, but not in mock-transfected clones. The
specificity of the vpr transcripts was further controlled by
Southern blot analysis, using a vpr probe recognizing an in-
ternal sequence of the PCR product (data not shown).
The vpr mRNA–positive clones were subsequently char-
acterized for the presence of vpr protein by immunopre-
cipitating extracts obtained from cells harvested during the
logarithmic growth with an anti-vpr–specific antibody (Fig.
1 
 
B
 
). The mobility of the protein detected in the vpr clones
was consistent with the 15 kD predicted size of vpr. The
levels of vpr expressed in the stable transfectants approxi-
mate those obtained at early steps (3–5 d) of an acute HIV
IIIB infection of Jurkat cells, as evaluated by both RNA-
PCR and immunoprecipitation analyses (data not shown).
 
HIV-1 vpr Expression Does Not Result in a Cell Cycle Arrest
in Jurkat Cells.
 
The vpr transfectants did not show any de-
lay in the rate of proliferation, as detected by trypan blue
dye exclusion, in comparison to the parental or mock-
transfected clones (data not shown). We then determined
the cell cycle distribution of the parental Jurkat cells, mock-
transfected, and vpr transfectants by measuring the DNA
content by flow cytometry. As shown in Fig. 2, the vpr 
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transfectants exhibited a G
 
2
 
/M:G1 ratio comparable to that
of parental cells or mock-transfected clones. Similar results
were obtained by the bromodeoxyuridine incorporation
method (data not shown).
 
Jurkat Cell Clones Stably Expressing vpr Are Less Susceptible
to Undergo Apoptosis Induced by TNF-
 
a
 
, Fas Triggering, and
Serum Starvation.
 
We then investigated whether the con-
stitutive expression of vpr could modulate the capacity of
Jurkat cells to undergo apoptosis. In a first set of experi-
ments, apoptosis induced by a combined treatment with
CHX and TNF-
 
a
 
 was evaluated by fluorescence micros-
copy. As shown in Fig. 3, the Jurkat parental cells (
 
b
 
) as
well as mock-transfected clones (
 
c
 
) displayed the typical apo-
ptotic morphology, characterized by chromatin condensa-
tion and clumping, as early as 4 h after treatment. In con-
trast, a marked reduction of all apoptotic parameters and of
the number of cells undergoing apoptosis was observed in
vpr transfected cells (
 
d
 
). Apoptotic cell death induced by
the combined treatment with CHX and TNF-
 
a
 
 was also
confirmed by flow cytometry analysis. As shown in Fig. 4,
the formation of the typical broad hypodiploid DNA peak
(sub G1 peak) characteristic of DNA bp fragmentation was
significantly reduced in vpr transfectants as compared to pa-
rental or mock-transfected clones.
In a set of independent experiments, the number of apo-
ptotic cells was specifically quantified by immunofluores-
cence after cell staining with Hoechst 33258 dye (49). As
shown in Fig. 5 (
 
A
 
), only a moderate percentage of vpr-
expressing cells underwent apoptosis upon addition of
CHX and TNF-
 
a
 
 (15.25% 
 
6
 
 1.2), whereas mock-trans-
fected cells could be induced to undergo marked levels of
apoptosis (55.62% 
 
6
 
 2.05).
To gain some insight into the possible cell target con-
trolled by the vpr, we investigated the effect of the consti-
tutive expression of this protein on the apoptosis induced
by stimuli acting through different signalling pathways (i.e.,
Fas triggering and 24 h of serum starvation). As shown in
Fig. 5 (
 
B
 
 and 
 
C
 
), a marked reduction in the percentage of
cells undergoing apoptosis was detected in all the vpr trans-
fectants after Fas stimulation (12.0% 
 
6
 
 1.13 versus 55.2% 
 
6
 
2.4) or serum starvation (7.75% 
 
6
 
 1.12 versus 23.0 
 
6
 
1.10), thus suggesting that putative mediator(s) common to
all these patterns are probably affected as result of the vpr
expression.
 
Vpr Antisense Phosphorothioate Oligodeoxynucleotide Renders
vpr-expressing Cells Highly Susceptible to Apoptosis Induced by
CHX and TNF-
 
a
 
.
 
To assess whether the decreased sus-
ceptibility of vpr-expressing cells to undergo apoptosis was
due to a direct effect of the endogenously expressed vpr,
we investigated the effect of antisense phosphorothioate oli-
Figure 1. Detection of vpr
mRNA and protein in trans-
fected clones. (A) Total cellular
RNA (1 mg) extracted from rep-
resentative mock-transfected
(CMV2 and CMV3) and vpr-
expressing (vpr4, vpr5, vpr7, vpr10)
clones or from acutely HIV-
infected Jurkat cells (4 d after
infection) was reverse transcribed
and the cDNA amplified by
PCR. The PCR products were
visualized by ethidium bromide
staining and their size deter-
mined in comparison with a
molecular weight marker (M). Amplification of the GAPDH mRNA was used as an internal control. (B) The expression of vpr protein was analyzed by
immunoprecipitation with a polyclonal antibody directed against recombinant HIV-1 vpr. The immune complexes were loaded on a 18% SDS-poly-
acrylamide gel and transferred to a filter. The filter was then blotted using an antibody directed against an NH2-terminal peptide of vpr, as described in
Materials and Methods. Cell lysates from acutely HIV-infected Jurkat cells (7 d after infection) were used as positive controls.
Figure 2. Cell cycle analysis of vpr-transfected cells. DNA analysis was
performed by PI staining. Histograms of flow cytometry analysis of DNA
content in Jurkat parental cells, a mock-transfected clone (CMV2), and
two vpr-expressing clones (vpr4 and vpr10) are shown. The abscissa indi-
cates red fluorescence (linear scale). In the ordinate, the relative cell num-
ber is indicated. The percentage of cells in the different phases of the cell
cycle was obtained as described in Materials and Methods. One represen-
tative experiment out of four is shown. Similar results were obtained with
all the other vpr-expressing and control clones (data not shown).407 Conti et al.
Figure 3. Morphological analysis of apoptosis induced by CHX and TNF-a. Jurkat parental cells (b), a mock-transfected (clone CMV2; c) and vpr-
expressing (clone vpr4; d) cells were stimulated with CHX (25 mg/ml) for 2 h and then treated with TNF-a (12.5 ng/ml) for an additional 2 h. Apoptosis
was evaluated by fluorescence microscopy using the chromatin dye Hoechst 33258. The apoptotic morphology is clearly visible in b and c, in which a
high number of cells show the typical condensation (arrows), fragmentation, and clumping (arrowheads) of chromatin, as compared to unstimulated parental
cells (a). In contrast, the vpr-expressing cells (d) are protected from apoptosis. All vpr transfectants and mock-transfected clones displayed a similar behavior
(data not shown).408 Regulation of Apoptosis by HIV-1 vpr Protein
godeoxynucleotide targeted to vpr, which had been tested
for their efficacy in blocking the expression of the vpr pro-
tein (data not shown). As shown in Fig. 6, only a moderate
percentage of vpr-expressing cells underwent apoptosis upon
addition of CHX and TNF-a (16.01%) as compared to
mock-transfected cells (49.20%). When antisense oligonu-
cleotide was added to the cell culture before the apoptotic
stimulus, the susceptibility of vpr-expressing cells to un-
dergo apoptosis was completely restored (45.97%). The
increased percentage of apoptotic cells in the presence of
antisense oligonucleotide was not due to oligonucleotide-
induced cellular toxicity, as assessed by trypan blue dye ex-
clusion (data not shown). Moreover, the addition of the con-
trol sense oligonucleotide did not exert any effect. Likewise,
the addition of either type of oligonucleotides to mock-
transfected clones did not exert any effect on the percent-
age of cells undergoing apoptosis. Similar results were ob-
tained with two other vpr-expressing clones (clone 9 and
10) and mock-transfected clones (clone 2 and 5) after in-
duction of apoptosis by CHX and TNF-a or Fas triggering
(data not shown). These results strongly indicate that the
resistance to the induction of apoptosis of vpr-expressing
cells is directly linked to vpr expression.
Analysis of bcl-2 and bax Proteins in vpr-expressing Cells.
Lastly, we investigated the possibility that vpr expression
was associated with any modulation of genes known to be
involved in the regulation of apoptosis. The intracellular
levels of bcl-2 and bax proteins were investigated by using
a specific flow cytometry analysis. As shown in Fig. 7 (top),
a 30% increase in the expression of bcl-2 protein was ob-
served in vpr-expressing clones as compared to the mock-
transfected or parental counterparts. We also investigated
the expression of bax, a cellular protein that binds to bcl-2
and suppresses its ability to block apoptosis. The intracellu-
lar levels of bax were significantly lower in vpr transfectants
(a 20% decrease) as compared to mock-transfected clones
(Fig. 7, top).
The expression of bcl-2 and bax proteins in vpr-express-
ing clones as well as in mock-transfected and parental cell
clones was further analyzed by immunoblotting with spe-
Figure 4. Flow cytometry analysis of cells stimulated with CHX and
TNF-a. Cells were stimulated as described in the legend to Fig. 3, stained
with PI, and then analyzed by a FACScanÒ flow cytometer. Bars (M1) in-
dicate cells in the hypodiploid compartment. A representative experiment
out of four is shown. The percentage of spontaneous apoptosis was ,1%.
Figure 5. Quantitation of the extent of apoptosis induced by CHX and
TNF-a, Fas triggering, and serum starvation. Vpr-expressing (Vpr) and
mock-transfected (CMV) clones were stimulated to undergo apoptosis
with a combination of CHX and TNF-a as described in the legend to
Fig. 3 (A), antibody to Fas (50 ng/ml for 4 h; B) and serum starvation (24 h;
C). Quantitative evaluation of apoptosis was performed by fluorescence
microscopy. The values of spontaneous apoptosis were in the range ,1%
up to a maximum of 2% for all clones. Results, expressed as percentage of
apoptotic cells, were obtained by counting at least 400 cells at a 500 mag-
nification in a blind code. Values represent the mean 6 standard errors of
the results obtained in six independent experiments. The values of the vpr
clones were statistically significant (i.e., P ,0.01 versus the values of the
control clones).409 Conti et al.
cific antibodies. The results of a representative experiment
shown in Fig. 7 (bottom) indicates that vpr expression results
in an upregulation of bcl-2 and in a parallel decrease in the
levels of bax.
Discussion
The immunopathogenesis associated with HIV-1 infec-
tion is characterized by several functional abnormalities and
by a progressive depletion of CD41 T lymphocytes. How-
ever, the mechanisms by which HIV kills CD41 T cells
have not yet been elucidated (50). Several mechanisms have
been proposed to explain the decline of CD41 T cells.
Some of them may be related to direct HIV-mediated cy-
topathic effects such as syncytia formation and single-cell kill-
ing (51). Other mechanisms may involve a series of immu-
nological phenomena, such as elimination of HIV-infected
CD4-positive cells by HIV-specific CTLs or by nonspecific
cytotoxic mechanisms (52), autoimmunity (53), or by an-
ergy induced by inappropriate signaling (54). Some studies
have shown that the cytopathic effect of HIV in mononu-
clear cell populations is associated with apoptosis and that
this phenomenon occurs in both CD41 and CD81 T lym-
phocytes of HIV-infected individuals (55–57). Abnormally
high levels of apoptotic cells are also detected in lymph nodes
of HIV-infected individuals (58). In general, intensity of
apoptosis correlates with the state of activation of the lym-
phoid tissue and not with stage of disease or viral burden
(58). Recent findings have indicated that apoptosis is rarely
observed in productively infected cells in the lymph nodes,
whereas it occurs predominantly in bystander uninfected
cells (59). This finding argues in favor of indirect mecha-
nisms for CD41 T cell depletion, rather than direct killing
of these cells by the virus. Consistent with this hypothesis,
it has been recently reported that coculture of HIV-infected
with uninfected cells results in cell death by apoptosis of
uninfected cells (60).
We have reported herein that the constitutive expression
of the HIV-1 vpr protein in Jurkat cells results in an im-
paired capacity of undergoing apoptosis induced by differ-
ent stimuli. The specific role of vpr in the cell protection
from apoptosis is demonstrated by the finding that antisense
vpr oligonucleotides render vpr-expressing cells as suscepti-
ble to apoptosis induced by CHX and TNF-a as the con-
trol clones. Our data may provide an explanation for the
apparent lack of apoptosis in HIV-infected cells. Moreover,
the antiapoptotic activity of vpr may have additional impli-
cations in the pathogenesis of HIV infection. Activation of
an endogenous cell suicide program represents a host strat-
egy to limit viral spread (25). In regards to HIV, it is of in-
terest to mention that Chinnaiyan et al. (61) very recently
suggested that apoptosis may serve as a beneficial host mech-
anism to limit viral spread. In particular, these authors dem-
onstrated that inhibition of proapoptotic ICE-like proteases
results in enhanced viral production in T lymphocytes ex-
posed to HIV-1. Many viruses encode genes inhibiting the
host cell death apparatus (25–35). Although there is evi-
dence that the HIV-1 tat protein is capable of influencing
apoptosis (36–42), the vpr protein exhibits the unique prop-
erty of being carried into the virions. This suggests that vpr
plays an important role in the first steps of infection, when
the regulatory proteins (tat and rev) are not yet present. It
should be noted that the vpr levels expressed in our trans-
fectants closely resemble those detectable at early stages
(3–5 d) of acute infection of Jurkat cells. At later stages
of infection, however, higher levels of vpr expression are
observed, in association with the peak of HIV replication (a
few days before cell death).
In this study, we also reported that the constitutive ex-
pression of vpr in Jurkat cells did not interfere with the
progression in the cell cycle. In fact, the vpr transfectants
exhibited a G2/M:G1 ratio comparable to that of parental
or mock-transfected cells. Several reports have demon-
strated that the expression of vpr at high levels, by either
transient or proviral DNA transfection, resulted in the inhi-
bition of the cell cycle (18–22). The apparent discrepancy
between our results and those from others could be ex-
plained by either the differences in the cell types and in the
Figure 6. Flow cytometry analysis of mock-transfected and vpr-express-
ing cells treated with phosphorothioate oligodeoxynucleotides targeted to
vpr. vpr-expressing cells (clone 4) and mock-transfected cells (clone 3)
were treated with phosphorothioate sense or antisense oligonucleotides as
described in Materials and Methods and then stimulated with CHX and
TNF-a. Apoptosis was evaluated by flow cytometry as described in the
legend to Fig. 4. Similar results were obtained in two additional experi-
ments.410 Regulation of Apoptosis by HIV-1 vpr Protein
experimental approaches used for achieving vpr expression
or by a dual effect of vpr. Notably, none of these papers
demonstrated a direct correlation between the concentra-
tion of vpr achieved into the cells and the extent of cell
cycle inhibition. Furthermore, the direct effect of vpr as in-
hibitor of cell cycle progression is supported only by ex-
periments in which proviruses, either wild type or mutated,
have been used. For instance, in the experiments published
by Bartz et al. (22) with the Jurkat cells, the G2 arrest was
observed in 59% of cells infected with vpr wild-type provi-
rus (multiplicity of infection 10) under experimental condi-
tions in which 100% of the cells were infected. Furthermore,
treatment of PBMCs with crude baculovirus supernatants
containing vpr resulted in inhibition of cell proliferation in
50–60% of the cells, depending on the stimulus used for
triggering T cell proliferation (44). In light of all these data,
it cannot be ruled out that vpr exerts a dual role depending
on its concentration. Interestingly, it has been reported by
Rogel et al. (18) that vpr expression in Jurkat cells, ob-
tained by infection at high multiplicity of infection with
vpr1 and vpr2 pseudotypes, resulted in cell cycle arrest 12 d
after infection, when the vpr expression achieved was prob-
ably very high. A recent study by Stewart et al. (43) showed
that the ability of vpr to arrest cells in the G2 phase finally
resulted in the induction of apoptosis without the addition
of exogenous stimuli. Notably, a vpr-mutated provirus
Figure 7. Effect of vpr on the expression of bcl-2 and bax proteins. The intracellular expression of bcl-2 and bax proteins was measured in vpr-express-
ing and mock-transfected clones by flow cytometry analysis (top) and by immunoblotting (bottom), as described in Materials and Methods. Quantitative
evaluation of bcl-2 and bax proteins was performed by converting the logarithmically amplified signals obtained by flow cytometry into values on a linear
scale. In vpr-expressing cells, the extent of bcl-2 increase and bax decrease with respect to mock-transfected control clones was of 30 and 20%, respec-
tively. These changes are the mean of three different experiments performed with three representative vpr-expressing clones, Jurkat parental cells, and
two mock-transfected clones. The increase of bcl-2 and the decrease of bax were highly reproducible in all the experiments. The statistical significance of
the values obtained was calculated by using the Kolmogorov-Smirnov test. A P ,0.001 was considered significant. The levels of bax expression in the Jurkat
parental cells was proved indistinguishable from those detected in mock-transfected clones (data not shown).411 Conti et al.
the physiological status of the target cell and probably on
many other factors (such as multiplicity of infection, virus
strain, cellular cofactors), a different expression of the vpr
protein could be obtained in different cells, thus allowing two
possible outcomes of the infection: (a) virus-induced cyto-
phatic effect at high vpr concentration; and (b) survival of
some infected cells at low vpr concentration. Notably, a
dual effect depending on the concentration of a viral pro-
tein has been previously described for the HIV Tat protein
(42). The fact that the same protein can determine different
effects in the host cell depending on its concentration would
provide the virus with a versatile and advantageous tool for
driving the cell fate from survival (persistence) to cell death
(cytophatic effect).
The nature of the vpr-induced signals involved in the
vpr action remains to be elucidated. The fact that vpr pro-
tects Jurkat cells from different apoptotic stimuli, either
protein synthesis dependent (Fas) or independent (TNF-a
and serum starvation), suggests that this protein acts on an
upstream step common to all these inducers. Our data indi-
cate that vpr may act, at least in part, by regulating the bal-
ance of cellular genes (bcl-2 and bax) involved in the regu-
lation of apoptosis.
Altogether, our results suggest that low levels of the en-
dogenous vpr protein can interfere with the physiological
turnover of T lymphocytes at early stages of virus infection,
thus facilitating HIV persistence and, subsequently, viral
spread. We suggest that the vpr protein could exert its ac-
tion upstream of the cell survival machinery, thus function-
ing as an endogenous regulator of the cell fate.
could also induce apoptosis, albeit at lower levels than the
wild-type provirus, indicating that other viral factors are in-
volved in the induction of apoptosis (43). More recently, it
has been reported that A1.1 cells treated with crude baculo-
virus supernatants containing vpr induced apoptosis in 50%
of the cells. In contrast, the same vpr treatment resulted in
the inhibition of apoptosis induced by anti-CD3 antibody (44).
This regulation of apoptosis was linked to vpr suppression
of NF-kB activity, via the induction of IkB. Nevertheless,
it should be noted that although the antiapoptotic activity
of exogenous vpr was studied in A1.1 cells, the NF-kB–
binding activity and IkB mRNA expression was investigated
in vpr-transfected rhabdomyosarcoma cells and PBMCs,
respectively (44). All this, together with the fact that the
crude baculovirus supernatants contained unknown amounts
of vpr, did not allow any definitive conclusions. Our study
is the first report on the inhibitory effect of vpr, constitu-
tively expressed at low levels in T cells, on apoptosis.
Although further studies are needed to clarify the role of
vpr in the pathogenesis of HIV infection, we envisage the
following scenario, taking into account all our results and
data from the literature: (a) the vpr protein imported into
the target cell could exert an antiapoptotic function in the
very early steps, thus allowing the establishment of the in-
fection; (b) the low levels of vpr expressed in the first days
after infection could continue to exert their antiapoptotic
activity; and (c) the high expression of vpr at late steps of
infection could result in cell growth arrest, subsequently lead-
ing to cell death. This scenario would take into account dif-
ferent aspects of the HIV life cycle. In fact, depending on
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